BI Asset Management Fondsmaeglerselskab’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $617K | Sell |
4,911
-26
| -0.5% | -$3.27K | 0.01% | 574 |
|
|
2025
Q1 | $546K | Sell |
4,937
-7,385
| -60% | -$817K | 0.01% | 556 |
|
|
2024
Q4 | $1.68M | Sell |
12,322
-4,923
| -29% | -$672K | 0.02% | 406 |
|
|
2024
Q3 | $1.99M | Buy |
17,245
+15,818
| +1,108% | +$1.82M | 0.03% | 285 |
|
|
2024
Q2 | $196K | Sell |
1,427
-3,510
| -71% | -$482K | ﹤0.01% | 560 |
|
|
2024
Q1 | $681K | Buy |
4,937
+1,235
| +33% | +$170K | 0.01% | 444 |
|
|
2023
Q4 | $488K | Buy |
3,702
+2,289
| +162% | +$302K | 0.01% | 530 |
|
|
2023
Q3 | $159K | Hold |
1,413
| – | – | ﹤0.01% | 639 |
|
|
2023
Q2 | $133K | Sell |
1,413
-9,457
| -87% | -$890K | ﹤0.01% | 654 |
|
|
2023
Q1 | $1.1M | Buy |
10,870
+6,456
| +146% | +$653K | 0.03% | 318 |
|
|
2022
Q4 | $527K | Buy |
+4,414
| New | +$527K | 0.01% | 411 |
|
|
2020
Q4 | – | Sell |
-158
| Closed | -$15K | – | 456 |
|
|
2020
Q3 | $15K | Buy |
+158
| New | +$15K | ﹤0.01% | 457 |
|